Αποτελέσματα Αναζήτησης
2 ημέρες πριν · On Tuesday, H.C. Wainwright maintained its Buy rating and $30.00 price target for Adverum Biotechnologies (NASDAQ: ADVM), expressing optimism about the company's upcoming clinical updates.The firm anticipates three significant updates in the fourth quarter of 2024, including the 52-week update from the Phase 2 LUNA trial, the Phase 1 OPTIC trial's 4-year clinical data, and additional design ...
- RBC cuts Adverum Biotech stock target on updated timelines
On Tuesday, RBC Capital Markets adjusted its outlook on...
- RBC cuts Adverum Biotech stock target on updated timelines
3 ημέρες πριν · REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for ...
2 ημέρες πριν · Adverum Biotechnologies has an analyst consensus of Strong Buy, with a price target consensus of $22.50. The company has a one-year high of $29.70 and a one-year low of $6.38. Currently, Adverum ...
2 ημέρες πριν · Adverum Biotechnologies, Inc. Condensed Consolidated Statements of Operations (In thousands except per share data) Three months ended September 30,: Nine months ended September 30,: 2024
2 ημέρες πριν · On Tuesday, RBC Capital Markets adjusted its outlook on shares of Adverum Biotechnologies (NASDAQ: ADVM), decreasing the price target to $10.00 from the previous $12.00, while maintaining a Sector Perform rating on the stock. The revision follows Adverum's third-quarter 2024 earnings report and the announcement of updated timelines for its forthcoming LUNA trial results and long-term follow-up ...
Get Adverum Biotechnologies Inc (ADVM.PH) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments
30 Σεπ 2024 · REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the third quarter of 2024 and provided updates to anticipated milestones.
